End-of-day quote
NORDIC GROWTH MARKET
23:00:00 30/01/2024 GMT
|
5-day change
|
1st Jan Change
|
0.82
SEK
|
+0.74%
|
|
-.--%
|
+36.67%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
229.2
|
152.1
|
116.5
|
101.9
|
32.71
|
25.66
|
Enterprise Value (EV)
1 |
223.1
|
139.2
|
115.4
|
93.7
|
18.92
|
24.99
|
P/E ratio
|
-28.1
x
|
-15.7
x
|
-9.19
x
|
-6.19
x
|
-1.72
x
|
-2.14
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
271
x
|
313
x
|
188
x
|
67.2
x
|
17.4
x
|
8.26
x
|
EV / Revenue
|
263
x
|
287
x
|
186
x
|
61.8
x
|
10
x
|
8.05
x
|
EV / EBITDA
|
-27.5
x
|
-15
x
|
-9.12
x
|
-6.17
x
|
-1.01
x
|
-2.15
x
|
EV / FCF
|
-44.4
x
|
-19.7
x
|
-16.5
x
|
-8.87
x
|
-1.62
x
|
-2.87
x
|
FCF Yield
|
-2.25%
|
-5.08%
|
-6.07%
|
-11.3%
|
-61.6%
|
-34.8%
|
Price to Book
|
28.6
x
|
9.24
x
|
31.4
x
|
8.46
x
|
1.88
x
|
4.77
x
|
Nbr of stocks (in thousands)
|
9,023
|
10,311
|
10,311
|
14,731
|
25,759
|
25,759
|
Reference price
2 |
25.40
|
14.75
|
11.30
|
6.920
|
1.270
|
0.9960
|
Announcement Date
|
13/04/18
|
12/04/19
|
14/04/20
|
13/04/21
|
14/04/22
|
14/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.8469
|
0.4854
|
0.6203
|
1.517
|
1.884
|
3.106
|
EBITDA
1 |
-8.117
|
-9.267
|
-12.65
|
-15.19
|
-18.66
|
-11.62
|
EBIT
1 |
-8.149
|
-9.31
|
-12.74
|
-15.4
|
-18.86
|
-11.94
|
Operating Margin
|
-962.14%
|
-1,917.88%
|
-2,053.48%
|
-1,015.06%
|
-1,000.92%
|
-384.47%
|
Earnings before Tax (EBT)
1 |
-8.148
|
-9.311
|
-12.74
|
-15.64
|
-19.03
|
-11.98
|
Net income
1 |
-8.148
|
-9.311
|
-12.74
|
-15.64
|
-19.03
|
-11.98
|
Net margin
|
-962.09%
|
-1,918.12%
|
-2,054.4%
|
-1,031.31%
|
-1,009.91%
|
-385.67%
|
EPS
2 |
-0.9031
|
-0.9400
|
-1.230
|
-1.118
|
-0.7387
|
-0.4650
|
Free Cash Flow
1 |
-5.026
|
-7.068
|
-7.005
|
-10.56
|
-11.65
|
-8.7
|
FCF margin
|
-593.39%
|
-1,456.11%
|
-1,129.26%
|
-696.23%
|
-618.55%
|
-280.12%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/04/18
|
12/04/19
|
14/04/20
|
13/04/21
|
14/04/22
|
14/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
6.03
|
12.9
|
1.11
|
8.23
|
13.8
|
0.67
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.03
|
-7.07
|
-7
|
-10.6
|
-11.7
|
-8.7
|
ROE (net income / shareholders' equity)
|
-109%
|
-76.1%
|
-126%
|
-198%
|
-129%
|
-105%
|
ROA (Net income/ Total Assets)
|
-58.7%
|
-42.6%
|
-62.6%
|
-79.2%
|
-61.1%
|
-47.8%
|
Assets
1 |
13.87
|
21.85
|
20.36
|
19.75
|
31.13
|
25.07
|
Book Value Per Share
2 |
0.8900
|
1.600
|
0.3600
|
0.8200
|
0.6700
|
0.2100
|
Cash Flow per Share
2 |
0.6700
|
1.250
|
0.2500
|
0.7400
|
0.6100
|
0.1200
|
Capex
|
-
|
0.43
|
-
|
-
|
0.21
|
0.01
|
Capex / Sales
|
-
|
88.38%
|
-
|
-
|
11.25%
|
0.23%
|
Announcement Date
|
13/04/18
|
12/04/19
|
14/04/20
|
13/04/21
|
14/04/22
|
14/04/23
|
|
1st Jan change
|
Capi.
|
---|
| +36.67% | 3.04M | | +10.79% | 124B | | -5.42% | 11.17B | | +4.17% | 9.17B | | -21.81% | 4.71B | | +8.79% | 3.44B | | -4.83% | 2.88B | | -12.05% | 2.11B | | -7.83% | 2.09B | | -22.84% | 1.8B |
Medical Devices & Implants
|